A COMPARATIVE STUDY OF ANTIMICROBIAL SENSITIVITY IN PATIENTS WITH ACUTE PYELONEPHRITIS AND EMPHYSEMATOUS PYELONEPHRITIS
DOI:
https://doi.org/10.70520/kjms.v18i3.602Keywords:
Acute Pyelonephritis, Emphysematous Pyelonephritis, Antibiotic Resistance, Antimicrobial, Sensitivity, Urinary Tract Infections (UTIs)Abstract
Objective: To determine the pathogens responsible for emphysematous pyelonephritis and compare it with acute pyelonephritis and their antimicrobial sensitivity patterns in these patients.
Methodology: A twelve-month prospective comparative observational study from July 2023 to June 2024, was conducted on 145 patients diagnosed with either acute pyelonephritis or EPN at the Institute of Kidney Disease, Peshawar. The patients over 18 years of age with a clinical diagnosis of acute or emphysematous pyelonephritis and a positive urine culture were included. Exclusion criteria included recent antibiotic use (within 14 days), pregnancy, chronic kidney disease, congenital urogenital anomalies, immunocompromised states, and incomplete patient data. Urine samples were cultured to identify causative microbes and assess their antibiotic sensitivity. The results were analyzed using SPSS 23.
Results: Among 145 patients, 72.4% had acute pyelonephritis and 27.6% had EPN. E. coli was the predominant pathogen in both conditions (64.8% in APN vs 60.0% in EPN, p=0.632). In acute pyelonephritis, highest sensitivity was observed for colistin (96.5%), amikacin (93.1%), and imipenem (93.1%). However, in EPN cases, sensitivity to these antibiotics was significantly lower (p=<0.01): colistin (76.3%), amikacin (76.3%), and imipenem (57.9%).
Conclusion: The study highlights a concerning rise in antimicrobial resistance, particularly in EPN cases. Colistin, aminoglycosides, and carbapenems remain effective, but potentially contributing to the resistance of these drugs. Adherence to WHO guidelines for antimicrobial prescription is essential to combat multidrug resistance.
References
1. Kibret M, Abera B. Prevalence and antibiogram of bacterial isolates from urinary tract infections at Dessie Health Research Laboratory, Ethiopia. Asian Pac J Trop Biomed. 2014;4(2):164-8.
2. Hummers-Pradier E, Kochen MM. Urinary tract infections in adult general practice patients. Br J Gen Pract. 2002;52(482):752-61.
3. Craig WD, Wagner BJ, Travis MD. Pyelonephritis: radiologic-pathologic review. Radiographics. 2008;28(1):255-77; quiz 327-8.
4. Smitherman KO, Peacock JE, Jr. Infectious emergencies in patients with diabetes mellitus. Med Clin North Am. 1995;79(1):53-77.
5. Thabet L, Messadi AA, Meddeb B, Mbarek M, Turki A, Ben Redjeb S. [Bacteriological profile of urinary tract infections in women in Aziza Othmana Hospital: 495 cases]. Tunis Med. 2010;88(12):898-901.
6. Minardi D, D'Angelo G, Santoro D, Conti A, Muzzonigro G. Urinary tract infections in women: etiology and treatment options. Int J Gen Med. 2011;4:333-43.
7. Koch GE, Johnsen NV. The Diagnosis and Management of Life-threatening Urologic Infections. Urology. 2021;156:6-15.
8. Kalantar Enayat FF, Nikkho Bahram. Asymptomatic bacteriuria among pregnant women referred to outpatient clinics in Sanandaj, Iran. Int Braz J Urol. 2008;34(6):699-704.
9. Patel MH, Trivedi GR, Patel SM, Vegad MM. Antibiotic susceptibility pattern in urinary isolates of gram-negative bacilli with special reference to AmpC beta-lactamase in a tertiary care hospital. Urol Ann. 2010;2(1):7-11.
10. Christaki E, Marcou M, Tofarides A. Antimicrobial Resistance in Bacteria: Mechanisms, Evolution, and Persistence. J Mol Evol. 2020;88(1):26-40.
11. De Oliveira DMP, Forde BM, Kidd TJ, Harris PNA, Schembri MA, Beatson SA, et al. Antimicrobial Resistance in ESKAPE Pathogens. Clin Microbiol Rev. 2020;33(3).
12. Fairley KF, Carson NE, Gutch RC, Leighton P, Grounds AD, Laird EC, et al. Site of infection in acute urinary tract infection in general practice. Lancet. 1971;2(7725):615-8.
13. Aalykke C, Kristensen S, Aalykke I. [Emphysematous pyelonephritis]. Ugeskr Laeger. 1992;154(20):1430-1.
14. Huang JJ, Tseng CC. Emphysematous pyelonephritis: clinicopathological classification, management, prognosis, and pathogenesis. Arch Intern Med. 2000;160(6):797-805.
15. Butt T, Leghari MJ, Mahmood A. In-vitro activity of nitrofurantoin in enterococcus urinary tract infection. J Pak Med Assoc. 2004;54(9):466-9.
16. Gaur P, Hada V, Rath RS, Mohanty A, Singh P, Rukadikar A. Interpretation of Antimicrobial Susceptibility Testing Using European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Clinical and Laboratory Standards Institute (CLSI) Breakpoints: Analysis of Agreement. Cureus. 2023;15(3):e36977.
17. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pan drug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268-81.
18. Barber AE, Norton JP, Spivak AM, Mulvey MA. Urinary tract infections: current and emerging management strategies. Clin Infect Dis. 2013;57(5):719-24.
19. Schaeffer AJ, Rajan N, Cao Q, Anderson BE, Pruden DL, Sensibar J, et al. Host pathogenesis in urinary tract infections. Int J Antimicrob Agents. 2001;17(4):245-51.
20. Abdul-Halim H, Kehinde EO, Abdeen S, Lashin I, Al-Hunayan AA, Al-Awadi KA. Severe emphysematous pyelonephritis in diabetic patients: diagnosis and aspects of surgical management. Urol Int. 2005;75(2):123-8.
21. Jakhere S, Yeragi B. Emphysematous pyelonephritis. Acta Med Indones. 2010;42(4):241-2.
22. Ngo XT, Nguyen TT, Dobbs RW, Thai MS, Vu DH, Dinh LQV, et al. Prevalence and Risk Factors of Mortality in Emphysematous Pyelonephritis Patients: A Meta-Analysis. World J Surg. 2022;46(10):2377-88.
23. Lu YC, Hong JH, Chiang BJ, Pong YH, Hsueh PR, Huang CY, et al. Recommended Initial Antimicrobial Therapy for Emphysematous Pyelonephritis: 51 Cases and 14-Year-Experience of a Tertiary Referral Center. Medicine (Baltimore). 2016;95(21):e3573.
24. Jang YR, Won J, Han J, Chung W, Ahn SJ. Comparison of antimicrobial resistance in patients with obstructive pyelonephritis associated with ureteral stones and uncomplicated pyelonephritis. Medicine (Baltimore). 2022;101(34):e30376.
25. Khawar Ali Shahzad FU, Khushi Muhammad, Farzana Khatoon, Mahmood Ul Hassan Qazi, Ishfaq Ahmed. Multiple Drug Resistance Pattern in Urinary Tract Infection Patients in Peshawar, Khyber Pakhtunkhwa (KPK) Province, Pakistan. Journal of Infection and Molecular Biology. 2013;1(4):67-70.
26. Khan IU, Mirza IA, Ikram A, Afzal A, Ali S, Hussain A, et al. Antimicrobial susceptibility pattern of bacteria isolated from patients with urinary tract infection. J Coll Physicians Surg Pak. 2014;24(11):840-4.
27. Lu YC, Chiang BJ, Pong YH, Chen CH, Pu YS, Hsueh PR, et al. Emphysematous pyelonephritis: clinical characteristics and prognostic factors. Int J Urol. 2014;21(3):277-82.
28. Jain A, Manikandan R, Dorairajan LN, Sreenivasan SK, Bokka S. Emphysematous pyelonephritis: Does a standard management algorithm and a prognostic scoring model optimize patient outcomes? Urol Ann. 2019;11(4):414-20.
29. Khalid Shahab AZM, Mohammad Areeb Iqbal, Munayal Roghani, Farhan Zeb, Umair Amin. Assessment of Microbial Diversity Pattern of Sensitivity and Antimicrobial Susceptibility in Patients Admitted with Urosepsis. Ann Pak Inst Med Sci. 2023;19(3):339-45.
30. Dunachie SJ, Day NP, Dolecek C. The challenges of estimating the human global burden of disease of antimicrobial resistant bacteria. Curr Opin Microbiol. 2020;57:95-101.
